{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:18:48Z","timestamp":1779322728625,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.leukres.2024.107481","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T16:20:29Z","timestamp":1710174029000},"page":"107481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Efficacy and safety of bosutinib in patients treated with prior imatinib and\/or dasatinib and\/or nilotinib: Subgroup analyses from the phase 4 BYOND study"],"prefix":"10.1016","volume":"139","author":[{"given":"B. Douglas","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Viqueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Leip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erinn Hoag","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2024.107481_bib1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2024.107481_bib2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107481_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","article-title":"The role of new tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"22","author":"Pophali","year":"2016","journal-title":"Cancer J."},{"key":"10.1016\/j.leukres.2024.107481_bib4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s11899-018-0449-7","article-title":"Tyrosine kinase inhibitors in the treatment of chronic-phase CML: strategies for frontline decision-making","volume":"13","author":"Kennedy","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2024.107481_bib5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2024.107481_bib6","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.leukres.2024.107481_bib7","unstructured":"European Medicines Agency. Bosulif (bosutinib) EPAR - product information. 2013 (Last update May 17, 2023). \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bosulif#:~:text=The%20active%20substance%20in%20Bosulif,the%20cells%20to%20divide%20uncontrollably\u3009. Accessed June 16, 2023."},{"key":"10.1016\/j.leukres.2024.107481_bib8","unstructured":"U.S. Food and Drug Administration. Bosulif (bosutinib) prescribing information. 2012 (Last update September 2022). \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203341lbl.pdf\u3009. Accessed June 16, 2023."},{"key":"10.1016\/j.leukres.2024.107481_bib9","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European leukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107481_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.leukres.2024.107481_bib11","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.2217\/fon-2019-0555","article-title":"The role of bosutinib in the treatment of chronic myeloid leukemia","volume":"16","author":"Gambacorti-Passerini","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.leukres.2024.107481_bib12","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","article-title":"Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107481_bib13","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/ajh.24536","article-title":"Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2024.107481_bib14","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2010.110","article-title":"Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy","volume":"24","author":"Giles","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107481_bib15","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107481_bib16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107481_bib17","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Rea","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107481_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107481_bib19","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","article-title":"Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107481_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clml.2016.03.004","article-title":"Cross-Intolerance with dasatinib among imatinib-intolerant patients with chronic phase chronic myeloid leukemia","volume":"16","author":"Khoury","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2024.107481_bib21","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-11-318949","article-title":"Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib","volume":"117","author":"Cortes","year":"2011","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262400047X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262400047X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T23:06:24Z","timestamp":1720134384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262400047X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":21,"alternative-id":["S014521262400047X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107481","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of bosutinib in patients treated with prior imatinib and\/or dasatinib and\/or nilotinib: Subgroup analyses from the phase 4 BYOND study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107481"}}